SOUTH
SAN FRANCISCO, Calif., March 1,
2023 /PRNewswire/ -- IDEAYA Biosciences, Inc.
(NASDAQ: IDYA), a synthetic lethality focused precision medicine
oncology company committed to the discovery and development of
targeted therapeutics, announced its participation in investor
conferences in March 2023.
Oppenheimer 33rd Annual Healthcare
Conference
Tuesday, March 14th, 2023
at 1:20 PM ET
- Fireside chat with Michael
White, Chief Scientific Officer and Darrin Beaupre, Chief Medical Officer, hosted by
Matthew Biegler, Executive Director
and Senior Analyst
Guggenheim 4th Annual Healthy Altitudes
Summit
Wednesday, March 15th,
2023 at 9:15 AM ET
- Fireside chat with Yujiro S.
Hata, Chief Executive Officer, hosted by Charles Zhu, Ph.D. Vice President and Equity
Research Analyst
A live audio webcast of conference events, as permitted by
conference host, will be available at the "Investors/News and
Events/Investor Calendar" section of the IDEAYA website at
https://ir.ideayabio.com/events. A replay of available
webcasts will be accessible for 30 days following the live
event.
About IDEAYA Biosciences
IDEAYA is a synthetic lethality-focused precision medicine
oncology company committed to the discovery and development of
targeted therapeutics for patient populations selected using
molecular diagnostics. IDEAYA's approach integrates
capabilities in identifying and validating translational biomarkers
with drug discovery to select patient populations most likely to
benefit from its targeted therapies. IDEAYA is applying its
early research and drug discovery capabilities to synthetic
lethality – which represents an emerging class of precision
medicine targets.
Forward-Looking Statements
This press release contains forward-looking statements,
including, but not limited to, statements related to participation
in and/or presentation at certain investor relations events. IDEAYA
undertakes no obligation to update or revise any forward-looking
statements. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to the business of IDEAYA in general, see IDEAYA's
Quarterly Report on Form 10-Q filed on August 15, 2022 and any current and periodic
reports filed with the U.S. Securities and Exchange Commission.
Investor and Media Contact
IDEAYA Biosciences
Paul Stone
Senior Vice President and Chief Financial Officer
investor@ideayabio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-to-participate-in-investor-conferences-in-march-2023-301758685.html
SOURCE IDEAYA Biosciences, Inc.